Nephro-Urology Monthly

Published by: Neoscriber Demo Publisher
Crossmark
Uncorrected Proof scheduled for 11 (2)

Urinary Neutrophil Gelatinase Associated Lipocalin (NGAL) in Predicting Cisplatin-Induced Acute Kidney Injury

Somayeh Sadat Shariatmaghani ORCID 1 , Alireza Saadat 2 , Isa Nazar 3 , Farnoush Davoudi 4 , * , Shahram Parvin 5 , Hossein Mehrani 5 and Behzad Einollahi 6
Authors Information
1 Department of Internal Medicine, Mashhad Univercity of Medical Science, Mashhad, Iran
2 Department of Onchology, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 Department of Epidemiology and Biostatistics, Mashhad University of Medical Sciences, Mashhad, Iran
4 Department of Community Medicine, Iran University of Medical Sciences, Tehran, Iran
5 Department of Biochemistry, Baqiyatallah University of Medical Sciences, Tehran, Iran
6 Department of Nephrology and Urology Research, Baqiyatallah University of Medical Sciences, Tehran, Iran
Article information
  • Nephro-Urology Monthly: In Press (In Press); e87523
  • Published Online: May 13, 2019
  • Article Type: Research Article
  • Received: December 14, 2018
  • Revised: March 6, 2019
  • Accepted: March 16, 2019
  • DOI: 10.5812/numonthly.87523

To Cite: Shariatmaghani S S, Saadat A, Nazar I, Davoudi F, Parvin S, et al. Urinary Neutrophil Gelatinase Associated Lipocalin (NGAL) in Predicting Cisplatin-Induced Acute Kidney Injury, Nephro-Urol Mon. Online ahead of Print ; In Press(In Press):e87523. doi: 10.5812/numonthly.87523.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Cohen SM, Lippard SJ. Cisplatin: From DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001;67:93-130. doi: 10.1016/s0079-6603(01)67026-0. [PubMed: 11525387].
  • 2. Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265-79. doi: 10.1038/sj.onc.1206933. [PubMed: 14576837].
  • 3. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2010;2(11):2490-518. doi: 10.3390/toxins2112490. [PubMed: 22069563]. [PubMed Central: PMC3153174].
  • 4. Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237(3):219-27. doi: 10.1016/j.toxlet.2015.06.012. [PubMed: 26101797]. [PubMed Central: PMC4516600].
  • 5. dos Santos NA, Carvalho Rodrigues MA, Martins NM, dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: An update. Arch Toxicol. 2012;86(8):1233-50. doi: 10.1007/s00204-012-0821-7. [PubMed: 22382776].
  • 6. Stohr W, Paulides M, Bielack S, Jurgens H, Koscielniak E, Rossi R, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer. 2007;48(2):140-7. doi: 10.1002/pbc.20812. [PubMed: 16724313].
  • 7. Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bokenkamp A, Blufpand H, van Dulmen-den Broeder E, et al. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. 2013;(10). CD008944. doi: 10.1002/14651858.CD008944.pub2. [PubMed: 24101439].
  • 8. Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994-1007. doi: 10.1038/sj.ki.5002786. [PubMed: 18272962].
  • 9. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010;30(6):570-81. doi: 10.1016/j.semnephrol.2010.09.005. [PubMed: 21146122].
  • 10. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci. 2007;334(2):115-24. doi: 10.1097/MAJ.0b013e31812dfe1e. [PubMed: 17700201].
  • 11. Endre ZH, Kellum JA, Di Somma S, Doi K, Goldstein SL, Koyner JL, et al. Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: Workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol. 2013;182:30-44. doi: 10.1159/000349964. [PubMed: 23689654].
  • 12. Devarajan P. Review: neutrophil gelatinase-associated lipocalin: A troponin-like biomarker for human acute kidney injury. Nephrology (Carlton). 2010;15(4):419-28. doi: 10.1111/j.1440-1797.2010.01317.x. [PubMed: 20609093].
  • 13. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004;24(3):307-15. doi: 10.1159/000078452. [PubMed: 15148457].
  • 14. Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: A critical evaluation of current status. Ann Clin Biochem. 2014;51(Pt 3):335-51. doi: 10.1177/0004563214521795. [PubMed: 24518531]. [PubMed Central: PMC4104776].
  • 15. Fliser D, Laville M, Covic A, Fouque D, Vanholder R; Ad-hoc working group of ERPB, et al. A European renal best practice (ERBP) position statement on the kidney disease improving global outcomes (KDIGO) clinical practice guidelines on acute kidney injury: Part 1: Definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27(12):4263-72. doi: 10.1093/ndt/gfs375. [PubMed: 23045432]. [PubMed Central: PMC3520085].
  • 16. Rostami Z, Nikpoor M, Einollahi B. Urinary neutrophil gelatinase associated lipocalin (NGAL) for early diagnosis of acute kidney injury in renal transplant recipients. Nephrourol Mon. 2013;5(2):745-52. doi: 10.5812/numonthly.9385. [PubMed: 23841038]. [PubMed Central: PMC3703133].
  • 17. Washburn KK, Zappitelli M, Arikan AA, Loftis L, Yalavarthy R, Parikh CR, et al. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant. 2008;23(2):566-72. doi: 10.1093/ndt/gfm638. [PubMed: 17911094].
  • 18. Peres LA, da Cunha AD, Assumpcao RA, Schafer A Jr, da Silva AL, Gaspar AD, et al. Evaluation of the cisplatin nephrotoxicity using the urinary neutrophil gelatinase-associated lipocalin (NGAL) in patients with head and neck cancer. J Bras Nefrol. 2014;36(3):280-8. doi: 10.5935/0101-2800.20140041. [PubMed: 25317609].
  • 19. Tekce BK, Uyeturk U, Tekce H, Uyeturk U, Aktas G, Akkaya A. Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage? Ann Clin Biochem. 2015;52(Pt 1):88-94. doi: 10.1177/0004563214528312. [PubMed: 24670880].
  • 20. Saadat A, Shariat Maghani SS, Rostami Z, Davoudi A, Davoudi F, Shafie A, et al. Normobaric hyperoxia preconditioning ameliorates cisplatin nephrotoxicity. Ren Fail. 2014;36(1):5-8. doi: 10.3109/0886022X.2013.832604. [PubMed: 24059271].
  • 21. Shahbazi F, Sadighi S, Dashti-Khavidaki S, Shahi F, Mirzania M. Urine ratio of neutrophil gelatinase-associated lipocalin to creatinine as a marker for early detection of cisplatin-associated nephrotoxicity. Iran J Kidney Dis. 2015;9(4):306-10. [PubMed: 26174458].
  • 22. Moon HH, Seo KW, Yoon KY, Shin YM, Choi KH, Lee SH. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol. 2011;17(30):3510-7. doi: 10.3748/wjg.v17.i30.3510. [PubMed: 21941418]. [PubMed Central: PMC3163249].
  • 23. Lin HY, Lee SC, Lin SF, Hsiao HH, Liu YC, Yang WC, et al. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci. 2013;29(6):304-11. doi: 10.1016/j.kjms.2012.10.004. [PubMed: 23684135].
  • 24. Sterling M, Al-Ismaili Z, McMahon KR, Piccioni M, Pizzi M, Mottes T, et al. Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy. Pediatr Blood Cancer. 2017;64(10). doi: 10.1002/pbc.26538. [PubMed: 28417544].
  • 25. Kos FT, Sendur MA, Aksoy S, Celik HT, Sezer S, Civelek B, et al. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy. Asian Pac J Cancer Prev. 2013;14(2):1111-4. doi: 10.7314/APJCP.2013.14.2.1111. [PubMed: 23621196].
  • 26. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231-8. doi: 10.1016/S0140-6736(05)74811-X. [PubMed: 15811456].
  • 27. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: A prospective study. Clin J Am Soc Nephrol. 2008;3(3):665-73. doi: 10.2215/CJN.04010907. [PubMed: 18337554]. [PubMed Central: PMC2386703].
  • 28. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;148(11):810-9. doi: 10.7326/0003-4819-148-11-200806030-00003. [PubMed: 18519927]. [PubMed Central: PMC2909852].
  • 29. Gaspari F, Cravedi P, Mandala M, Perico N, de Leon FR, Stucchi N, et al. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: A pilot prospective case-control study. Nephron Clin Pract. 2010;115(2):c154-60. doi: 10.1159/000312879. [PubMed: 20407275].
  • 30. Barresi V, Ieni A, Bolignano D, Magno C, Buemi M, Barresi G. Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: Correlation with histotype and histological grade. Oncol Rep. 2010;24(2):305-10. doi: 10.3892/or_00000860. [PubMed: 20596614].
  • 31. Marti J, Fuster J, Hotter G, Sola AM, Deulofeu R, Modolo MM, et al. Serum neutrophil gelatinase-associated lipocalin in patients with colorectal liver metastases: preliminary results of an exploratory prospective study. Int J Biol Markers. 2010;25(1):21-6. doi: 10.1177/172460081002500103. [PubMed: 20306447].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments